There are no Transcripts on SPHS.
Tue, Sep. 16, 4:54 PM
Fri, Aug. 8, 12:27 PM
Tue, May. 20, 12:46 PM
Tue, May. 13, 5:34 PM
Mon, Apr. 14, 12:45 PM
Thu, Mar. 13, 5:40 PM
Sep. 16, 2013, 12:46 PM
Sep. 10, 2013, 11:18 AM
- Sophiris Bio (SPHS +2.4%) moves up after Stifel Nicolaus initiated the shares with a Buy rating and a $9 price target.
- The firm says Phase II studies of PRX302 demonstrated statistically significant reduction in benign prostatic hyperplasia symptoms.
- The data shows the drug has a sound mechanism of action and Stifel feels it has a high likelihood of success in Phase III trials
- Additionally, the drug's further development will benefit from management's proven record of developing therapeutics and selling companies.
Aug. 22, 2013, 5:30 PM
SPHS vs. ETF Alternatives
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. The Company is engaged in research and development of products for the treatment of urological diseases. It is currently developing PRX302 for treatment of benign prostatic hyperplasia.
Other News & PR